Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 9/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.38 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501595 | 0.92 | MCL1 (0.46) | MCL1BCL2L1PLA2G2AFFAR4 | |
| SCHEMBL6502699 | 0.91 | MCL1 (0.46) | MCL1LMNAPLA2G2AFFAR4 | |
| SCHEMBL6500708 | 0.91 | MCL1 (0.47) | MCL1BCL2L1 | |
| SCHEMBL6502915 | 0.90 | SMN1; SMN2 (0.44) | MCL1BCL2L1PPARGLMNASMN1; SMN2 | |
| SCHEMBL6489668 | 0.90 | MCL1 (0.44) | MCL1BCL2L1PPARGLMNASMN1; SMN2 | |
| SCHEMBL6492318 | 0.90 | MCL1 (0.49) | MCL1BCL2L1 | |
| SCHEMBL6489649 | 0.90 | MCL1 (0.44) | MCL1PPARGPLA2G2AFFAR4 | |
| SCHEMBL6501386 | 0.90 | MCL1 (0.48) | MCL1PLA2G2AFFAR4 | |
| SCHEMBL6503536 | 0.89 | MCL1 (0.46) | MCL1PPARGPLA2G2AFFAR4 | |
| SCHEMBL6489813 | 0.89 | MCL1 (0.43) | MCL1PPARGPLA2G2AFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | claimed |
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | MCL1 806/4885BCL2L1 1036/4885PPARG 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.